논문 목록
12건 · 최신순-
Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed metabolic and aesthetic medicine, yet their potential influence on botulinum toxin type A (BoNT-A) pharmacodynamics remains unexplored. Using the AesthetiSIM™ microsimul…
-
Computational model-informed comparative evaluation of botulinum toxin a formulations: A 20-year simulation of onset, diffusion, duration, and immunogenicity.
Comparative evaluation of botulinum neurotoxin type A (BoNT/A) formulations is limited by short clinical trials and lack of long-term safety data. This study applied a validated multiscale computational model (AesthetiSIM™) to simulate 20 y…
-
Breaking the 4-hour rule: Multiscale computational modelling redefines post-injection restrictions for botulinum neurotoxin A.
This study used a validated, literature anchored multiscale modelling platform (AesthetiSIM) to investigate whether common post injection behaviours influence the early distribution of botulinum toxin A (BoNT A). A cohort of 10,000 paired d…
- Unraveling the Intricacies of Early Complications in Hyaluronic Acid Filler Procedures: A Scholarly Critique and Analysis.
-
Integrative Assessment for Optimizing Aesthetic Outcomes When Treating Glabellar Lines With Botulinum Toxin Type A: An Appreciation of the Role of the Frontalis.
Despite the perception that treatment of glabellar lines with botulinum toxin A is straightforward, the reality is that the glabellar region contains a number of interrelated muscles. To avoid adverse outcomes, practitioners need to appreci…
- Botulism Due to Cosmetic Injection of Botulinum Toxin: Five-Year Experience.
- Hyaluronidase in Practice: A Survey of Dermatologic and Plastic Surgeons in the United States and Canada.
-
Retrospective review of delayed adverse events secondary to treatment with a smooth, cohesive 20-mg/mL hyaluronic acid filler in 4500 patients.
[BACKGROUND] Recent publications have suggested an increased risk of delayed adverse events (DAEs) with a smooth, cohesive 20-mg/mL hyaluronic acid filler, Juvéderm Voluma (HA-V). [OBJECTIVE] To examine the occurrence of HA-V DAEs and iden…
-
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).
[BACKGROUND] DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A formulation in clinical development. A phase 2 dose-ranging study identified an optimal dose and demonstrated efficacy with a median duration of 24 week…
-
Delayed-onset nodules secondary to a smooth cohesive 20 mg/mL hyaluronic acid filler: cause and management.
[BACKGROUND] The shift from 2- to 3-dimensional soft tissue augmentation has allowed the development of hyaluronic acid (HA) fillers, which are long lasting and also reversible. Delayed-onset inflammatory nodules have recently been reported…
-
Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid.
Soft tissue augmentation plays an increasingly important role in the management of the aging face. The recent explosion of dermal filler use in aesthetic dermatology has brought with it the expected reporting of rare but significant side ef…
- Caveat emptor (buyer beware).